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Abstract 
Objective: Diabetic large nerve fibre dysfunction, as measured by vibration perception 
threshold (VPT) predicts foot ulceration, amputation and mortality. Thus, determination of 
modifiable risk factors is of great clinical importance. 
 
Research Design and Methods: We assessed 1407 patients with type 1 diabetes and normal 
VPT participating in the EURODIAB Prospective Complications Study, at baseline mean age 
32.7+10.2 years; mean diabetes duration 14.7+9.3 years; and mean follow-up of 7.3+0.6 
years. VPT was measured using biothesiometry on the right big toe and medial malleolus.  An 
abnormal result was defined as >2SD from the predicted mean for the patient s age.  
 
Results: An abnormal VPT was associated with an increased incidence of gangrene, 
amputation, foot ulceration, leg bypass or angioplasty and mortality (p<0.02).  The incidence 
of abnormal VPT was 24% over the 7.3 year follow-up.  Duration of diabetes and HbA1c 
significantly influenced the incidence of abnormal VPT (p<0.0001).  After correction for 
these, established risk factors for cardiovascular disease including, male sex (p=0.0004), 
hypertension (p<0.0001), total cholesterol (p=0.002), LDL cholesterol (p=0.01), smoking 
(p<0.0001), weight (p<0.0001); and diabetic complications (retinopathy (p=0.0001), 
nephropathy (p=0.01) and autonomic neuropathy (p=0.001)) were all found to be significant 
risk factors.  A previous history of cardiovascular disease doubled the incidence of abnormal 
VPT. 
 
Conclusions: This prospective study indicates that cardiovascular risk factors predict 
development of large fibre dysfunction.  This may account for the high mortality rate in 
patients with abnormal VPT, and emphasises the importance of an early determination of 
VPT to detect sub-clinical neuropathy, and to address cardiovascular risk factors. 
 
Keywords  Diabetic neuropathy, Cardiovascular risk factors, Type 1 Diabetes Mellitus, 
Epidemiology 
 
Abbreviations  VPT: vibration perception threshold, AER: albumin excretion rate, CAN: 
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Chronic diabetic peripheral neuropathy (DPN) is a slowly progressive process, the 
pathogenesis of which is poorly understood.  However, we do know that large fibre 
dysfunction, as measured by vibration perception threshold (VPT) predicts foot ulceration, 
lower-limb amputation and mortality (1-3).  The consequences of these clinical complications 
results in a massive economic burden, estimated in 2001 to be $10.9 billion in the US (4, 5).  
Early in the natural history of the disease patients are usually asymptomatic.  Thus reliable 
identification of individuals in the early stages of the neuropathic process is required so that 
more rigorous modification of risk factors and foot-care education can be implemented.  The 
best method to identify such patients is still a matter of some debate (6-9).  
 
In patients with type 2 diabetes the prevalence of abnormal VPT has been shown to be 11.4% 
(10) and the incidence of an abnormal VPT was 19.9% over a 12 year period (11).  Some 
investigators have used absolute values of VPT as predictors of foot ulceration.  In one study 
a VPT >25V was associated with a seven-fold increase in ulcer risk, compared to individuals 
with a VPT <15V (12).  Another study found an incidence of 7.2% of first foot ulceration 
within 1 year in patients with a VPT >25 (13).  In addition, a cut-off of 25V has been shown 
to be a more sensitive way of detecting patients at risk of foot ulceration than the 10g 
monofilament (14).  Small fibre dysfunction may be determined by measuring thermal 
thresholds, but in terms of discriminating between patients with and without ulceration it does 
not appear to provide any additional value above measuring VPT (15).  
 
Thus ample evidence exists to highlight the clinical importance of an abnormally high VPT, 
but as yet there is little evidence examining the risk factors involved in its development.  Poor 
glycaemic control is associated with an abnormal VPT even at diagnosis in patients with type 
2 diabetes (16).  Evidence also exists to suggest that height is a determinant of VPT (10, 17).  
Importantly, VPT is known to increase with age (18, 19).  The majority of research regarding 
large fibre dysfunction, as measured by VPT, has been conducted in patients with type 2 
diabetes.  In this study we have examined the incidence of abnormal VPT in a large cohort of 
patients with type 1 diabetes, in order to identify possible modifiable risk factors. 
 
Research Design and Methods 
 
Study design  The EURODIAB Prospective Complications Study recruited 3250 patients 
(1668 men and 1582 women; mean [+SD] age, 32.7+10.2 years; mean duration of diabetes, 
14.7+9.3 years).  Subjects with type 1 diabetes were randomly selected from 31 diabetes 
clinics across Europe.  The selection criteria and methods have been described in detail 
previously (20, 21).  The study was approved by the ethics committee at each centre and 
written informed consent was gained from all subjects.  All measurements were obtained by 
trained physicians following standardised procedures.  The baseline examinations were 
conducted from 1989 to 1991, and a subsequent follow-up visit occurred between 1997 and 
1999. 
 
Assessment of vibration perception threshold (VPT) was measured by centrally calibrated 
biothesiometers (Bio-Medical Instrument Company, Newbury, Ohio, USA).  Three readings 
on the right big toe and right medial malleolus were obtained and averaged.  Results were 
classified according to age-related criteria (19). 
 
Neuropathy was defined as the presence of two or more of the following criteria: the presence 
of one or more symptoms, the absence of two or more reflexes of the ankle or knee tendons 
(with reinforcement if necessary), an abnormal VPT and the presence of CAN, as described 
previously (21).  Symptoms of neuropathy were present if the subject had experienced any of 
the following in the preceding six months: “asleep” numbness or “dead feeling” in the feet, a 
prickling sensation in the feet, deep aching or burning pains in the  legs, unusual difficulty in 
climbing stairs, difficulty with bladder control, and nocturnal diarrhoea.  Symptoms were 
assessed carefully to exclude non-diabetic causes.   
 
Blood samples, taken after an overnight fast, if possible, were sent to central laboratories.  In 
order to compare the results with those of the DCCT, measured glycosylated haemoglobin 
values were converted as previously reported (22).  Lipid measurements included total 
cholesterol, HDL cholesterol and triglycerides.  Levels of LDL cholesterol were calculated. 
 
Urinary albumin excretion rate (AER) was obtained from a single 24-h urine collection.  An 
AER between 20 and 200 g/min was defined as microalbuminuria, while >200 g/min was 
defined as macroalbuminuria.  Diabetic retinopathy was determined from centrally graded 
retinal photographs and was either classified as non-proliferative (background) or 
proliferative. 
 
Cardiovascular disease (CVD) was defined as either a history of physician-diagnosed 
cardiovascular disease (e.g., previous myocardial infarction, angina, coronary-artery bypass 
grafting, or stroke) or ischaemic changes on a 12-lead electrocardiogram (classified by two 
observers according to the Minnesota Code). 
 
Of the 3250 patients examined at baseline, 722 had abnormal VPT, whereas 1407 with normal 
VPT were assessed at follow-up (Figure 1).  Baseline investigations and determination of 
VPT were repeated after a mean period of 7.3+0.6 years of follow-up. 
Statistical analysis The data were analysed using the statistical package SAS (version 8).  A 
p-value less than 0.05 was considered statistically significant.  Where variables were 
continuous and normally distributed the t-test was used to compare group means.  If, 
however, the variable had a skewed distribution the Mann-Whitney U test was used to 
compare group medians and the variable was log transformed for any subsequent analysis.  
To compare group percentages the chi-square test was used.  
 
In order to assess which risk factors were associated with the development of VPT multiple 
logistic regression was used to calculate odd ratios adjusted for HbA1c and duration.  So that 
the odds ratios could be compared, for each risk factor standardised odds ratios were 
calculated.  For a continuous variable this was the odds ratio associated with an increase of 1 
standard deviation (SD), and for a dichotomous variable the reference group was those 
patients without the respective risk factor.  
 
Similarly, multiple logistic regression was used to assess which variables were associated 
with the incidence of VPT while adjusting for all other key risk factors. 
 
In order to assess the effect of glycaemic exposure on the incidence of abnormal VPT linear 
regression was performed by the centre to compare the results of HbA1c measured locally and 
centrally at the same time, both at baseline.  This provided a formula to convert locally 
measured HbA1c to the centralized assay at each centre.  An average of all local HbA1c which 
had been measured for each patient, prior to the baseline visit, was calculated and converted 
to the central measure. 
 
A breakpoint or threshold effect for the relation between HbA1c and progression to abnormal 
VPT was tested by a two phase segmented weighted regression, where two straight lines are 
fitted through a series of defined points.  These points were calculated by logistic regression 
adjusted for diabetes duration.  This segmented regression was compared to the line of best fit 
using weighted linear regression.  Logistic regression was also used to test for a threshold.  
 
Results 
 
Baseline characteristics according to whether VPT was assessed at follow-up 
The baseline characteristics of the 1407 patients examined in this study were compared to 
those that qualified for follow-up (n=660), but did not have a follow-up assessment.  Those 
that died or did not have VPT assessed at follow-up had higher baseline glycosylated 
haemoglobin (8.5 vs 8.1%, p<0.0001), waist-to-hip ratios (0.85 vs 0.84, p=0.04), systolic 
blood pressure (118 vs 116mmHg, p=0.05), total cholesterol (5.35 vs 5.21mmol/l, p=0.005), 
LDL-cholesterol (3.37 vs 3.27 mmol/l, p=0.05) and triglyceride levels (0.96 vs 0.87mmol/l, 
p<0.0001).  In addition, they were more likely to have a history of smoking (51 vs 46%, 
p=0.03), proliferative retinopathy (8 vs 5%, p=0.02) and had lower Von Willebrand factor 
levels (1.09 vs 1.14U/ml, p=0.02).  
  
 Incidence of clinical outcomes 
An abnormal VPT at baseline predicted the incidence of several lower-limb complications, 
i.e., foot ulcers 7.7 vs 1.7% (p<0.0001), leg bypass or angioplasty 1.6 vs 0.4% (p=0.02), 
gangrene 2.2 vs 0.6% (p=0.004), amputation 2.4 vs 0.4% (p=0.0004) and indeed mortality 8.0 
vs 2.1% (p<0.0001). 
 
Risk factors for the development of an abnormal VPT 
Of the 1407 patients with normal VPT at baseline, an abnormal VPT developed in 333 at 
follow-up, an incidence of 23.7%.  Table 1 shows baseline characteristics of the study group 
divided into those that had an abnormal versus normal VPT at follow-up.  Patients that 
developed abnormal VPT were significantly older (2.5 years), with longer duration of 
diabetes (2.2 years), poorer blood glucose control (HbA1c 0.6% higher) and were taller (2 cm) 
at baseline than those patients who maintained a normal VPT.  Furthermore, patients that 
developed an abnormal VPT had significantly higher levels of traditional cardiovascular risk 
factors, i.e., male sex, history of smoking, weight, body-mass index, waist-to-hip ratio, 
hypertension, total cholesterol, LDL-cholesterol, triglycerides, history of cardiovascular 
disease and lower HDL-cholesterol levels.  They were also more likely to have established 
complications of diabetes, i.e., micro- or microalbuminuria, higher albumin excretion rates, 
any retinopathy, proliferative retinopathy, and cardiac autonomic neuropathy.   
 
By adjusting for the established confounding factors of duration of diabetes and HbA1c, risk 
factors for the development of an abnormal VPT were determined using regression analysis, 
Table 2.  Virtually all the traditional risk factors of cardiovascular disease and established 
complications of diabetes remained significantly associated with the development of 
abnormal VPT, the only exception being HDL-cholesterol.  The risk factors with the highest 
odds ratios were macroalbuminuria and proliferative retinopathy, i.e., 2.48 and 2.17 
respectively. Furthermore, as expected taller patients were more likely to develop an 
abnormal VPT, and this association remained statistically significant after also adjusting for 
male sex, OR = 1.38 (1.16, 1.64), p=0.003.   
 
 
Multivariate Models 
In order to examine independent associations between key risk factors and the incidence of 
abnormal VPT multiple logistic regression analysis was performed, Table 3.  In Model 1 the 
analysis mutually adjusted for the presence of all other risk factors.  It was found that duration 
of diabetes, glycosylated haemoglobin value, triglyceride, body-mass index, history of 
smoking and presence of hypertension at baseline remained significantly associated with the 
incidence of abnormal VPT.  The relation between total cholesterol level and the incidence of 
abnormal VPT did not reach statistical significance, and neither did albumin excretion rate.  
The strongest relation was with history of smoking, which carried an odds ratio of 1.71, and 
the second strongest relation was with hypertension with an odds ratio of 1.65. 
 
When complications of diabetes were added to the model (Table 3, Model 2) duration of 
diabetes as expected was not statistically significant.  Glycosylated haemoglobin value, 
triglyceride, body-mass index, history of smoking and presence of hypertension at baseline 
remained significantly related to the incidence of abnormal VPT.  In addition, the presence of 
cardiovascular disease at baseline was independently related to the incidence of abnormal 
VPT, with an odds ratio of 2.13.  The relation between any retinopathy and abnormal VPT 
was not significant, p = 0.1. 
 
As expected chronic glycaemic exposure was higher in the group who developed an abnormal 
VPT (HbA1c 0.3% higher, p=0.001).  When the above analyses were repeated using the 
adjusted mean HbA1c the findings were virtually identical.  Furthermore, when the 
relationship between HbA1c and progression to abnormal VPT was tested there was no 
threshold effect. 
 
Conclusions 
Determination of vibration perception threshold using a biothesiometer is a quick and easy 
way of detecting large fibre dysfunction, and therefore identifies patients at risk of foot 
ulceration, lower-limb amputation and mortality (1, 2).  During a period of 12 years, the 
incidence of abnormal VPT in patients with type 2 diabetes is estimated to be 19.9% (11).  In 
this larger prospective study of patients with type 1 diabetes we observed an incidence of 
23.7% over 7.3 years of follow-up.  Apart from glycaemic control and duration of diabetes we 
have demonstrated that cardiovascular risk factors such as hypertension, smoking, obesity, 
elevated triglyceride levels and the presence of cardiovascular disease at baseline appear to 
predict the development of abnormal VPT.  The patients who qualified for follow-up, but 
were not assessed had worse glycaemic and cardiovascular profiles and hence our results 
may, if anything, have underestimated the associations.  The same independent risk factors 
have previously been shown to be related to newly diagnosed DPN (21).  Both hypertension 
and a history of smoking were strong risk factors for development of neuropathy, and 
abnormal VPT.  As expected a higher mean HbA1c predicted the development of abnormal 
VPT, but no threshold effect was identified.  A similar outcome was found in a previous study 
of a mixed cohort of type 1 and type 2 diabetes patients (9). 
 
An abnormal VPT at baseline predicted the development of foot ulcers, leg bypass or 
angioplasty, gangrene, amputation and mortality.  This finding is consistent with previous 
studies (12, 13).  In a general diabetes clinic it is probably more important to routinely use a 
test which is highly sensitive, as opposed to highly specific, as the potential risk of DPN being 
under diagnosed is greater than the risk of over preventative measures being implemented in 
patients with false-positive results.  Such measures include foot-care education, and more 
frequent follow-up, for instance in podiatry-led neuropathy clinics (23).  Studies have shown 
that measurement of VPT is more sensitive than the 10g monofilament in assessing foot ulcer 
risk (14).  Despite this evidence, at present monofilaments are routinely used in outpatient 
clinics.  Whilst the loss of ability to feel a 10g monofilament is known to predict ulceration 
(13), it usually occurs at a late stage in the disease process.  Conversely, an abnormal VPT is 
often evident earlier in the natural history of the disease (24).  Another advantage of the VPT 
method is that it provides a quantitative result, and for each unit increase, the risk of foot 
ulceration increases (13). 
 
It is well recognised that patients with diabetes are at increased cardiovascular disease risk.  
Within the EURODIAB cohort, in cases where the cause of mortality is known, CVD was the 
cause of death in ~40% of subjects (25).  This present study shows that even in a young 
cohort of patients with type 1 diabetes (average age 32.7 years at baseline) an abnormal VPT 
identifies a subset of patients with adverse cardiovascular risk parameters.  This knowledge 
enables identification of those patients in need of more aggressive treatment of their CVD risk 
factors.  The all-cause mortality rate of patients with an abnormal VPT at baseline was four 
times higher than those with a normal value, 8 versus 2% over 7.3 years follow-up.   
 
In conclusion, determination of an abnormal VPT is important for two reasons.  Firstly, it 
identifies a cohort of patients with large fibre dysfunction and its inherent clinical risks, and 
secondly, it identifies a population at increased cardiovascular risk.  Therefore, intensive 
management of cardiovascular risk factors could not only reduce cardiovascular events, but 
also the clinical sequelae of neuropathy.  
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Table 1.  Baseline characteristics of 1407 patients according to the incidence of 
abnormal VPT.* 
 
Variable Progression to  
abnormal VPT 
Maintenance of  
normal VPT 
p-value 
Number of patients 333 1074  
Age (yr) 33.410.2 30.98.8 <0.0001 
Duration of diabetes (yr) 14.89.0 12.68.1 <0.0001 
Male sex (%) 56 46 0.001 
History of smoking (%) 56 42 <0.0001 
Height (cm) 1709 1689 0.0004 
Weight (kg) 70.110.8 65.510.1 <0.0001 
Body-mass index 24.33.0 23.22.6 <0.0001 
Waist-to-hip ratio 0.850.11 0.830.10 0.0053 
HbA1c (%) 8.62.0 8.01.8 <0.0001 
Insulin dose / kg body weight (IU) 0.670.21 0.690.22 0.1 
Total cholesterol (mmol/l) 5.451.17 5.141.02 <0.0001 
LDL-cholesterol (mmol/l) 3.481.05 3.200.91 0.0005 
HDL-cholesterol (mmol/l) 1.460.44 1.520.42 0.04 
Triglyceride (mmol/l) 0.95 (0.54, 2.55) 0.84 (0.48, 2.06) <0.0001 
Fibrinogen (g/l) 3.260.95 3.150.87 0.1 
Von Willebrand factor (U/ml) 1.25 (0.64, 2.32) 1.10 (0.54, 2.11) 0.0005 
Systolic Blood pressure (mm Hg) 117 (98, 152) 116 (96,140) 0.06 
Diastolic Blood pressure (mm Hg) 75 (57, 93) 73 (57, 92) 0.09 
Hypertension (%) 27 15 <0.0001 
History of cardiovascular disease (%) 11 6 0.005 
Albumin excretion rate (g/min) 12.6 (3.7, 447.4) 9.5 (3.2, 122.5) <0.0001 
Macroalbuminuria (%) 9.5 3.3 <0.0001 
Micro- or Macroalbuminuria (%) 33 22 <0.0001 
Any retinopathy (%) 52 33 <0.0001 
Proliferative retinopathy (%) 9 4 0.0001 
Cardiac autonomic neuropathy (%) 39 28 0.0001 
 
*   Plus-minus values are means +SD.  Alternatively, in cases of skewed distributions, data are medians (5
th
 
percentile, 95
th
 percentile).  P values are derived from Student’s t-test or, in cases of skewed distributions from a 
Mann-Whitney U test and in cases of percentages from a chi-squared test. 
The blood pressure data exclude patients who were undergoing antihypertensive therapy  
  
     
Table 2.  Risk factors for the incidence of abnormal VPT after adjustment for HbA1c 
and duration of diabetes.*     
     
Variable Odds ratio (95% CI) p-value 
Male sex (%) 1.58 (1.23 - 2.04) 0.0004 
History of smoking (%) 1.69 (1.31 - 2.18) <0.0001 
Height (cm) 1.40 (1.22 - 1.59) <0.0001 
Weight (kg) 1.64 (1.44 - 1.86) <0.0001 
Body-mass index 1.43 (1.26 - 1.62) <0.0001 
Waist-to-hip ratio 1.17 (1.04 - 1.32) 0.009 
Insulin dose / kg body weight (IU) 0.88 (0.77 - 0.99) 0.05 
Total cholesterol (mmol/l) 1.22 (1.08 - 1.39) 0.002 
LDL-cholesterol (mmol/l) 1.22 (1.04 - 1.42) 0.01 
HDL-cholesterol (mmol/l) 0.90 (0.79 - 1.02) 0.10 
Triglyceride (mmol/l) 1.35 (1.15 - 1.57) 0.002 
Von Willebrand Factor (U/ml) 1.27 (1.08 - 1.51) 0.005 
Hypertension (%) 1.88 (1.38 - 2.56) <0.0001 
History of cardiovascular disease (%) 1.62 (1.04 - 2.52) 0.03 
Albumin excretion rate (g/min) 1.29 (1.14 - 1.45) <0.0001 
Macroalbuminuria (%) 2.48 (1.47 - 4.19) 0.0006 
Micro- or Macroalbuminuria (%) 1.44 (1.08 - 1.93) 0.01 
Any retinopathy (%) 1.88 (1.36 - 2.61) 0.0001 
Proliferative retinopathy (%) 2.17 (1.22 - 3.86) 0.008 
Cardiac autonomic neuropathy (%) 1.58 (1.20 - 2.07) 0.001 
    
* Standardized odds ratios are expressed per SD increase in each continuous risk factor.  Odds ratios for 
dichotomous variables have as a reference group those patients without the respective risk factor.  CI denotes 
confidence interval.  
Log transformation was used 
 
Table 3.  Odds Ratios for Associations between Key Risk Factors and the Incidence of 
Abnormal VPT with the Use of Two Logistic-Regression Models.* 
 
 Model 1  Model 2  
Variable Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value 
Duration of diabetes (yr) 1.21 (1.03 - 1.43) 0.02 1.12 (0.90 - 1.39) 0.3 
HbA1c (%) 1.26 (1.06 - 1.49) 0.008 1.30 (1.07 - 1.68) 0.009 
History of smoking (%) 1.71 (1.23 - 2.37) 0.001 1.85 (1.27 - 2.70) 0.01 
Hypertension (%) 1.65 (1.08 - 2.50) 0.02 1.82 (1.12 - 2.94) 0.01 
Body-mass Index 1.32 (1.12 - 1.56) 0.001 1.26 (1.04 - 1.53) 0.002 
Total cholesterol (mmol/l) 1.06 (0.88 - 1.27) 0.6 0.94 (0.76 - 1.17) 0.6 
Triglyceride (mmol/l) 1.21 (1.01 - 1.45) 0.04 1.27 (1.03 - 1.58) 0.03 
Albumin excretion rate (g/min) 1.15 (0.98 - 1.35) 0.09 1.20 (1.00 - 1.44) 0.05 
History of cardiovascular disease (%)   2.13 (1.10 - 4.12) 0.03 
Any retinopathy (%)   1.44 (0.92 - 2.26) 0.1 
  
*     Standardized odds ratios are expressed per SD increase in each continuous risk factor.  Odds ratios for 
dichotomous variables have as a reference group those patients without the respective risk factor.  CI denotes 
confidence interval.  
Log transformation was used 
Model 1 – mutually adjusted for all other risk factors 
Model 2 – mutually adjusted for all other risk factors and complications of diabetes 
 
